相关实验视频

Updated: Jan 9, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

埃塞俄比亚心血管疾病患者的药物相关问题和促成因素:系统性审查和元分析

Mengistie Yirsaw Gobezie¹, Nuhamin Alemayehu Tesfaye², Mulat Belete Demessie²

¹Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia. zemen.girum@gmail.com.

Systematic reviews

|December 2, 2025

概括

与药物相关的问题 (MRPs) 的高患病率影响了埃塞俄比亚74%的心血管疾病 (CVD) 患者. 需要进行干预措施,以改善这些人的药物管理和患者结果.

科学领域:

药物监督药物监督药物监督
公共卫生公共卫生
临床药房临床药房

背景情况:

心血管疾病 (CVD) 是一个主要的全球健康问题.
埃塞俄比亚在控制心血管疾病方面面临着重大挑战,特别是与药物相关的问题 (MRPs).

研究的目的:

系统地审查和对埃塞俄比亚心血管疾病患者中MRP的流行情况进行元分析.
为了确定这种患者群体中常见的MRPs和促成因素.

主要方法:

遵守PRISMA指南和PROSPERO注册 (CRD42024501087) 的要求.
在PubMed,Hinari,Embase和Scopus上进行全面的文献搜索.
使用加权逆随机效应模型进行元分析,并进行子组和灵敏度分析.

主要成果:

在22项研究中,在5700名心血管疾病患者中,MRPs的综合患病率为74% (95% CI 66-81).
平均每患者1.65个MRP,不遵守 (18%),无效治疗 (16%) 和需要额外的药物 (15%) 是常见的.
多药性,患者参与度低,并发症和疾病持续时间被确定为促成因素.

结论:

高MRP患病率需要有针对性的干预措施,以优化埃塞俄比亚心血管疾病患者的药物管理.
医疗保健提供者应优先考虑个性化护理,定期药物审查和患者教育.
解决MRPs对于改善心血管疾病管理中的患者结果至关重要.

关键词:

心血管疾病的心血管疾病.埃塞俄比亚埃塞俄比亚埃塞俄比亚与药物相关的问题.进行元分析分析.系统性审查系统性审查与毒品相关的未满足的需求.

更多相关视频

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

相关概念视频

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...

Assessment of the Cardiovascular System I: Subjective Data

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...